• Incyte reported positive pivotal Phase 2 results for oral ALK2 inhibitor zilurgisertib in fibrodysplasia ossificans progressiva; data were presented at ENDO 2026.
• The study showed reduced disease progression signals, including fewer new bone-forming lesions and lower flare activity, with benefits sustained through 48 weeks.
• FDA accepted the FOP New Drug Application under Priority Review, setting a PDUFA target action date of Sept. 26, 2026.
• Safety profile supported continued development, with treatment generally well tolerated in the placebo-controlled period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief on June 14, 2026, and is solely responsible for the information contained therein.